Table 2.
Demographic and clinical characteristics of the study population.
| Overall (N = 20) | ICM (N = 9) | DCM (N = 11) | p value | |
|---|---|---|---|---|
| Age (years) | 59.80 ± 12.81 | 62.33 ± 8.26 | 57.73 ± 15.70 | 0.439 |
| Male n (%) | 18 (90.0) | 8 (88.9) | 10(90.9) | 0.881 |
| Hypertension n (%) | 13 (65) | 5 (55.6) | 8 (72.7) | 0.423 |
| Diabetes n (%) | 5 (25) | 3 (33.3) | 2 (18.2) | 0.436 |
| NYHA | ||||
| II | 9 (45.0) | 4 (44.4) | 5 (45.4) | |
| III | 8 (40.0) | 4 (44.4) | 4 (36.4) | |
| IV | 3 (15.0) | 1 (11.2) | 2 (18.2) | |
| Systolic BP (mmHg) | 119.20 ± 19.60 | 119.00 ± 20.89 | 119.36 ± 19.51 | 0.968 |
| Diastolic BP (mmHg) | 69.95 ± 9.94 | 71.78 ± 9.431 | 68.45 ± 10.55 | 0.472 |
| Heart rate (per min) | 77.50 ± 14.61 | 79.44 ± 17.01 | 75.91 ± 12.95 | 0.604 |
| LVEF (%) | 33.10 ± 6.45 | 37.44 ± 4.64 | 29.55 ± 5.56 | 0.003** |
| LVEDD (mm) | 68.60 ± 11.37 | 59.22 ± 3.31 | 76.27 ± 9.63 | 0.000** |
| LVESD (mm) | 58.00 ± 11.63 | 48.22 ± 3.15 | 66.00 ± 9.61 | 0.000** |
| NT-proBNP (ng/l) | 4,755.05 ± 5,432.78 | 5,505.11 ± 7,707.28 | 4,141.36 ± 2,763.38 | 0.590 |
| Medication | ||||
| β-Blockers n (%) | 19(95.0) | 8 (88.9) | 11 (100.0) | 0.257 |
| ACEI or ARB n (%) | 12(60.0) | 4 (44.4) | 8 (72.7) | 0.199 |
| Diuretics n (%) | 14(70.0) | 6 (66.7) | 8 (72.7) | 0.769 |
Values are mean with SD (±) or absolute numbers with relative frequencies (%) at the time of study enrolment. LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; LEVSD, left ventricular end diastolic diameter pro; ACEI, inhibitors of angiotensin converting enzyme; ARB, angiotensin receptor blocker; BP, blood pressure; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association. **p < 0.01.